Decrease of plasma prekallikrein and kallikrein inhibitors during intravenous phlebography.
Complex contact activation systems may have major involvement in side effects of i.v. contrast media. To investigate this, quantitative measurements of several factors (plasma prekallikrein, kallikrein inhibitory activity, haematocrit, alpha-2-macroglobulin, antithrombin III, alpha-1-antitrypsin and beta-thromboglobulin) were made before and after i.v. contrast phlebography in two groups of patients (each containing 21 patients) with no thrombosis, using a high- (meglumine iodamide) and a low-osmolality (ioxaglate) contrast medium. A statistically significant decrease in plasma prekallikrein was observed after the high-osmolality contrast medium, which is a sign of the activation of the kallikrein-kinin system and an indicator of the activation of the intrinsic coagulation. These events may play an important role in the adverse effects of contrast media.
D000990:Antithrombin III / Q000032:analysis; D003287:Contrast Media / Q000633:toxicity*; D006400:Hematocrit; D006801:Humans; D007451:Iodamide / Q000031:analogs & derivatives / Q000633:toxicity*; D007458:Iodipamide / Q000031:analogs & derivatives; D007463:Iodobenzoates / Q000633:toxicity*; D007485:Ioxaglic Acid / Q000633:toxicity*; D007610:Kallikreins / Q000037:antagonists & inhibitors* / Q000097:blood*; D010690:Phlebography; D011288:Prekallikrein / Q000097:blood*; D000515:alpha 1-Antitrypsin / Q000032:analysis; D000511:alpha-Macroglobulins / Q000032:analysis; D001620:beta-Thromboglobulin / Q000032:analysis
D003287:Contrast Media; D007463:Iodobenzoates; D000515:alpha 1-Antitrypsin; D000511:alpha-Macroglobulins; D001620:beta-Thromboglobulin; D007451:Iodamide; D000990:Antithrombin III; D011288:Prekallikrein; D007610:Kallikreins; D007458:Iodipamide; C006753:meglumine iodipamide; D007485:Ioxaglic Acid